BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 2013; 1(2): 74-78 [PMID: 24303470 DOI: 10.12998/wjcc.v1.i2.74]
URL: https://www.wjgnet.com/2218-6190/full/v1/i2/74.htm
Number Citing Articles
1
M. M. Kudishina, I. V. Kozlova, E. A. Yavaeva. Skin manifestations of inflammatory bowel diseasesExperimental and Clinical Gastroenterology 2020; (3): 113 doi: 10.31146/1682-8658-ecg-175-3-113-117
2
Wenjuan Chen, Hui Xu, Xiuxiu Wang, Junying Gu, Huizi Xiong, Yuling Shi. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysisInternational Immunopharmacology 2015; 28(1): 146 doi: 10.1016/j.intimp.2015.05.049
3
Masashi Ohno, Shigeki Koyama, Mariko Ohara, Kazumi Shimamoto, Yu Kobayashi, Fumiyasu Nakamura, Kazuki Mitsuru, Akira Andoh. Pyoderma Gangrenosum with Ulcerative Colitis Successfully Treated by the Combination of Granulocyte and Monocyte Adsorption Apheresis and CorticosteroidsInternal Medicine 2016; 55(1): 25 doi: 10.2169/internalmedicine.55.5422
4
Sven R. Quist, Luise Kraas. Therapieoptionen beim Pyoderma gangraenosumJDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(1): 34 doi: 10.1111/ddg.13173_g
5
Mark Fleisher, Jan Marsal, Scott D. Lee, Laura E. Frado, Alyssa Parian, Burton I. Korelitz, Brian G. Feagan. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel DiseaseDigestive Diseases and Sciences 2018; 63(4): 825 doi: 10.1007/s10620-018-4971-1
6
Mauro Mastronardi, Elisabetta Cavalcanti, Nunzia Labarile, Raffaele Armentano, Francesco Gabriele, Margherita Curlo. Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte/monocyte apheresis as a new therapeutic option refractory cases – a case report and literature reviewTherapeutic Advances in Chronic Disease 2023; 14 doi: 10.1177/20406223231194190
7
Ho D. Na, Hongfei Yan, Chul H. Park. Misdiagnosis of Pyoderma Gangrenosum Increases Medical Costs and Prolongs Hospital Stay: A Case ReportThe International Journal of Lower Extremity Wounds 2023; 22(2): 428 doi: 10.1177/15347346211011870
8
Kentaro Tominaga, Kenya Kamimura, Hiroki Sato, Masayoshi Ko, Yuzo Kawata, Takeshi Mizusawa, Junji Yokoyama, Shuji Terai. Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current statusWorld Journal of Clinical Cases 2020; 8(11): 2092-2101 doi: 10.12998/wjcc.v8.i11.2092
9
Sven R. Quist, Luise Kraas. Treatment options for pyoderma gangrenosumJDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(1): 34 doi: 10.1111/ddg.13173
10
Tomoyoshi Shibuya, Keiichi Haga, Michio Saeki, Mayuko Haraikawa, Hitoshi Tsuchihashi, Koki Okahara, Osamu Nomura, Hirofumi Fukushima, Takashi Murakami, Dai Ishikawa, Shigaku Ikeda, Akihito Nagahara. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresisJournal of Clinical Apheresis 2020; 35(5): 488 doi: 10.1002/jca.21821
11
Smaranda Diaconescu, Silvia Strat, Gheorghe G. Balan, Carmen Anton, Gabriela Stefanescu, Ileana Ioniuc, Ana Maria Alexandra Stanescu. Dermatological Manifestations in Pediatric Inflammatory Bowel DiseaseMedicina 2020; 56(9): 425 doi: 10.3390/medicina56090425
12
Anastasia Atanasova Chokoeva, José Carlos Cardoso, Uwe Wollina, Georgi Tchernev. Pyoderma gangrenosum—a novel approach?Wiener Medizinische Wochenschrift 2017; 167(3-4): 58 doi: 10.1007/s10354-016-0472-z
13
Ignacio Marin-Jimenez, Guillermo Bastida, Ana Forés, Esther Garcia-Planella, Federico Argüelles-Arias, Pilar Sarasa, Ignacio Tagarro, Alonso Fernández-Nistal, Carmen Montoto, Mariam Aguas, Javier Santos-Fernández, Marta Maia Bosca-Watts, Rocio Ferreiro, Olga Merino, Xavier Aldeguer, Xavier Cortés, Beatriz Sicilia, Francisco Mesonero, Manuel Barreiro-de Acosta. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE studyBMJ Open Gastroenterology 2020; 7(1): e000351 doi: 10.1136/bmjgast-2019-000351
14
Rafael Luís Luporini, Pâmela Cristina Bellaz Do Amaral Campos Silva, Miguel Regueiro. Hidradenitis suppurativa: Coexistence or dermatological extraintestinal manifestation of Crohn's disease?Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1151370
15
Jia-Huei Zheng, Shian-Ren Lin, Feng-Jen Tseng, May-Jywan Tsai, Sheng-I Lue, Yi-Chen Chia, Mindar Woon, Yaw-Syan Fu, Ching-Feng Weng. Clerodane Diterpene Ameliorates Inflammatory Bowel Disease and Potentiates Cell Apoptosis of Colorectal CancerBiomolecules 2019; 9(12): 762 doi: 10.3390/biom9120762
16
Ripalta Colìa, Addolorata Corrado, Francesco Paolo Cantatore. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseasesAnnals of Medicine 2016; 48(8): 577 doi: 10.1080/07853890.2016.1195011
17
Eva Remenyik. European Handbook of Dermatological Treatments2023; : 297 doi: 10.1007/978-3-031-15130-9_27
18
Akiko Arimura, Miho Hatanaka, Hiromi Katsue, Shigeto Matsushita, Takuro Kanekura. Granulocyte and monocyte adsorption apheresis for paradoxical reaction to infliximabThe Journal of Dermatology 2015; 42(4): 438 doi: 10.1111/1346-8138.12789
19
R. E. Faulkes. Upper limb erythema nodosum: the first presentation of Crohn's diseaseClinical Case Reports 2014; 2(5): 183 doi: 10.1002/ccr3.87
20
Lisa Younge. Dermatological complications to consider when managing IBD patientsGastrointestinal Nursing 2015; 13(4): 34 doi: 10.12968/gasn.2015.13.4.34
21
Laurent Peyrin-Biroulet, Gert Van Assche, David Gómez-Ulloa, Laura García-Álvarez, Núria Lara, Chris M. Black, Sumesh Kachroo. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology 2017; 15(1): 25 doi: 10.1016/j.cgh.2016.06.025